Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and ASA404 in Advanced Urothelial Carcinoma
NCT01071928Phase 2Withdrawn
- Sponsor
- Hoosier Cancer Research Network
- Start
- Jun 2010
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of vadimezan in urothelial carcinoma (UC), sponsored by Hoosier Cancer Research Network. Primary endpoint: Overall Response Rate at 12 months. Planned start Jun 2010; status: withdrawn.
02
Drugs
vadimezan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01071928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071928.